The Markey Cancer Center (MCC) Cancer Research Informatics (CRI) Shared Resource Facility facilitates collaborative research among members of the MCC through the optimal application of informatics technologies and methods that maximize the accessibility and usability of data, information, and knowledge for cancer research. The primary goal of CRI is to provide comprehensive and centralized data acquisition and informatics support that is readily available to cancer center members.
The Specific Aims of the CRI are to: 1. Develop and support innovative technologies for funded research studies that facilitate accurate, timely, and secure data acquisition and dissemination. 2. Maintain and support a comprehensive patient-centered data warehouse offering unique opportunities for MCC investigators to utilize integrated data sets from diverse sources ranging from genetic biomarkers to population-based surveillance data. 3. Facilitate rapid and efficient recruitment of patients to investigator-initiated trials and other research studies. 4. Facilitate investigator access to data, biospecimens, and patients from Kentucky's Appalachian population. 5. Ensure the interoperability of informatics systems in compliance with evolving data standards. 6. Collaborate with the University of Kentucky (UK) Division of Biomedical Informatics to provide novel and state-of-the-art informatics solutions that increase the efficiency and accuracy of information and knowledge derived from diverse data sources.
The CRI is a critical resource supporting the acquisition, storage, management and utilization of data, information, and knowledge. The CRI integrates data from population, clinical, and research sources to identify and recruit study participants, annotate biospecimens, and derive unique research datasets for MCC investigators. This shared resource provides value-added service to MCC members, which has led to numerous publications and research grants from the NCI and other funding agencies.
|Wei, Xiaowei; Xu, Yong; Xu, Fang Fang et al. (2017) RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells. Cancer Res 77:1345-1356|
|Cui, Jiajun; Xu, Wenhua; Chen, Jian et al. (2017) M2 polarization of macrophages facilitates arsenic-induced cell transformation of lung epithelial cells. Oncotarget 8:21398-21409|
|Wu, Yadi; Wang, Yu; Lin, Yiwei et al. (2017) Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun 8:14228|
|Wise, James T F; Wang, Lei; Zhang, Zhuo et al. (2017) The 9th Conference on Metal Toxicity and Carcinogenesis: The conference overview. Toxicol Appl Pharmacol 331:1-5|
|Carpenter, Brittany L; Liu, Jinpeng; Qi, Lei et al. (2017) Integrin ?6?4 Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation. Sci Rep 7:6174|
|Jarrett, Stuart G; D'Orazio, John A (2017) Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis. Photochem Photobiol 93:245-258|
|Li, Liqing; Li, Xiang; Qi, Lei et al. (2017) The role of talin2 in breast cancer tumorigenesis and metastasis. Oncotarget 8:106876-106887|
|Kenlan, Dasha E; Rychahou, Piotr; Sviripa, Vitaliy M et al. (2017) Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells. Mol Cancer Ther 16:831-837|
|Son, Young-Ok; Pratheeshkumar, Poyil; Divya, Sasidharan Padmaja et al. (2017) Nuclear factor erythroid 2-related factor 2 enhances carcinogenesis by suppressing apoptosis and promoting autophagy in nickel-transformed cells. J Biol Chem 292:8315-8330|
|Arnold, Susanne M; Chansky, Kari; Leggas, Markos et al. (2017) Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs 35:608-615|
Showing the most recent 10 out of 281 publications